Drug profile · INN
oteseconazole
VIVJOA
oteseconazole (VIVJOA) is a lanosterol 14-alpha demethylase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — oteseconazole
- US status
- approved
- Class
- Antiinfectives for systemic use (J02)
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
oteseconazole (VIVJOA) is a lanosterol 14-alpha demethylase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Lanosterol 14-alpha demethylase inhibitor
Primary target: Lanosterol 14-alpha demethylase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is oteseconazole?
oteseconazole (VIVJOA) is a lanosterol 14-alpha demethylase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for oteseconazole?
VIVJOA is a marketed brand name for oteseconazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of oteseconazole?
oteseconazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.